Repros says FDA seeks more studies for testosterone drug

(Reuters) – Repros Therapeutics Inc said the U.S. health regulator sought additional studies of its testosterone replacement drug, Androxal, and recommended that a safety study of the drug be extended, delaying potential approval. Shares of the company fell 33 percent in premarket trading. Repros said the company’s marketing approval application would be delayed to the fourth quarter of 2014, if the results of the study have to be included. The company was earlier expecting to file the application in mid-2014. Analysts said the slight delay could be a positive. …